Briefly, TRPA1 may promote mitochondrial morphology and dysfunction by triggering ERS and up-regulating GRP75 expression to induce mitochondrial calcium overload, whereas TRPA1 inhibitor HC-030031 protects against cisplatin-induced ERS-mitochondrial damage and reduces calcium overload in AKI. Here, TRPA1 is linked to acute kidney injury.